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Abstract 
 
Objectives: To assess potential mechanisms of cortical superficial siderosis (cSS), a central 
MRI biomarker in cerebral amyloid angiopathy (CAA), we performed a collaborative meta-
analysis of APOE associations with cSS presence and severity. 
Methods: We pooled data from published studies reporting APOE genotypes and MRI 
assessment of cSS, in three distinct settings: (a) stroke clinic patients with symptomatic CAA 
(i.e. lobar intracerebral hemorrhage, transient focal neurological episodes) according to 
Boston criteria; (b) memory clinic patients; and (c) population-based studies. We compared 
cSS presence and severity (focal or disseminated vs. no cSS) in participants with e2+ or e 4+ 
genotype vs. the e3/e3 genotype, by calculating study-specific and random effects pooled, 
unadjusted ORs. 
Results: Thirteen studies fulfilled inclusion criteria: seven memory clinic cohorts (n=2587), 
five symptomatic CAA cohorts (n=402) and one population based study (n=1379). There was 
no significant overall association between APOE e4+ and cSS presence or severity. When 
stratified by clinical setting, APOE e4+ was associated with cSS in memory clinic (OR: 2.10; 
95%CI: 1.11-3.99), but not symptomatic CAA patients. The pooled OR showed significantly 
increased odds of having cSS for APOE e2+ genotypes (OR: 2.67, 95% CI 2.31-3.08), in both 
patient populations. This association was stronger for disseminated cSS in symptomatic CAA 
cohorts. In detailed subgroup analyses, APOE e2/e2 and APOE e2/e4 genotypes were most 
consistently and strongly associated with cSS presence and severity. 
Conclusion: CAA-related vasculopathic changes and fragility associated with APOE e2+ 
allele might have a biologically meaningful role in the pathophysiology and severity of  cSS. 
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Introduction 
Cortical superficial siderosis (cSS) is detected as curvilinear hypointensities following the 
cortical surface on blood-sensitive T2*-weighted gradient-recalled echo (T2*-GRE) and 
susceptibility-weighted (SWI) MRI sequences.1 It is generally thought that cSS reflects deposits 
of blood-breakdown products in the outermost cortical layers from, often occult, convexal 
subarachnoid hemorrhage.1, 2 cSS is particularly common in advanced cerebral amyloid 
angiopathy (CAA) (prevalence 40-60%),1, 3, 4 a small vessel disease that results from amyloid-β 
deposition in cortical and leptomeningeal arterioles. In CAA patients, cSS seems to be 
consistently associated with increased risk of incident5 and recurrent6 lobar intracerebral 
hemorrhage (ICH), including early recurrence,7 as well as future dementia.8 cSS is hence now 
considered a third cardinal hemorrhagic signature of CAA,1, 9 alongside multiple strictly lobar 
cerebral microbleeds and lobar ICH. It is also included in the modified Boston criteria, as a 
specific MRI biomarker of the disease.2 
The emerging clinical relevance of cSS, either as direct contributor to CAA-related 
impairment or a biomarker of the disease’s presence, severity and course, raises questions 
about the mechanisms of this imaging lesion. However, data from neuropathological studies 
remain extremely limited. Understanding the underlying mechanisms and vascular pathology 
contributing to cSS could be facilitated by identifying associations with Apolipoprotein E 
(APOE) alleles. Associations between APOE e2 or e4 alleles with both lobar ICH risk and 
CAA presence and severity on neuropathology have been previously described. In fact, APOE 
genotype seem to be the single most important genetic determinant of CAA pathophysiology, 
identified to date.10, 11 The current hypothesis, albeit supported by limited data, is that APOE 
e4 enhances vascular amyloid-β deposition in a dose-dependent fashion,12 while APOE e2 
promotes, so-called, CAA-related vasculopathic changes (vessel cracking, detachment and 
delamination of the outermost layer of the tunica media and fibrinoid necrosis) which can lead 
to vessel rupture.13 It is hypothesized that cSS results from bleeding-prone leptomeningeal or 
superficial cortical arterioles that harbour advanced CAA and associated vasculopathic 
changes.1 
To gain further insights into potential mechanisms of cSS in CAA and small vessel 
disease, we performed a collaborative meta-analysis of all available published studies that 
provided APOE data according to cSS presence and severity. Since cSS appears to convey high 
risk of recurrent ICH, it might segregate with APOE genotypes that are associated with CAA-
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related vasculopathic changes. Hence, we specifically tested the hypothesis that cSS presence 
and severity is associated with APOE e2, a marker of CAA-related small vessel fragility. 
Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
The study was performed according to a predefined protocol (i.e. before collecting and 
analysing data) designed in house and finalised in January 2016. This report was prepared with 
reference to the PRISMA,14 the MOOSE15 guidelines and the Cochrane Handbook for 
Systematic Reviews of Interventions. 
Study identification and selection criteria 
We sought all studies of adult humans published in any language that reported APOE genotype 
data and had cSS assessment on MRI, regardless of whether any association between the two 
was reported. We searched PubMed and Embase (from inception to January 2016 and updated 
in November 2017) using a combination of keyword search and MeSH terms, i.e. ("cortical 
superficial siderosis" OR "convexity siderosis" OR "convexal siderosis" OR "cortical 
hemosiderosis" OR siderosis OR hemosiderosis) AND (APOE OR "apolipoprotein E"). We 
also screened the references lists of all relevant studies and reviews identified, and searched 
Google Scholar for other studies citing potentially eligible relevant studies. We included 
relevant studies with >20 participants, including studies that recruited individuals from three 
distinct settings: (a) patients presenting to stroke clinics with symptomatic sporadic CAA (i.e. 
lobar intracerebral haemorrhage, transient focal neurological episodes) according to the 
validated classic Boston criteria (i.e. cSS was not part of CAA diagnosis); (b) memory clinic 
patients; and (c) participants from population-based studies. The rationale for including 
individuals from these different clinical settings was twofold. First, they represent the most 
likely clinical scenarios in which cSS in small vessel disease is detected on MRI (a and b) and 
are of potential clinical significance. Second, they capture the spectrum of cardinal CAA 
phenotypes:  relatively “pure” stroke presentations (including lobar intracerebral 
haemorrhage), cognitive impairment/dementia, or incidental findings in elderly healthy 
populations. 
We excluded case reports, small case series, and studies including hereditary/familial 
forms of CAA. Two authors independently selected eligible studies, resolving disagreements 
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by discussion. When two or more studies with overlapping cohorts existed, we included only 
the study providing the most data about the association and the largest number of participants. 
Data extraction 
Eligible studies were classified according to the primary clinical setting as (a) symptomatic 
CAA; (b) memory clinics; or (c) population-based. For each included study, we extracted 
information using standard proformas on publication year, country in which the study was 
conducted, study design, participant source and baseline demographic/clinical characteristics. 
For our planned meta-analyses, we extracted, or required from authors summary-level 
data on numbers of participants with each APOE genotype (i.e. e3e3, e2 e3, e3e4, e4e4, 
e2e2, e2e4) according to cSS presence and severity (focal or disseminated) where available. 
A structured data extraction form was created and completed as far as possible by entering 
data from the relevant publication(s) and/or circulated to authors and a collaborative group 
was established. We also extracted information on the MRI sequence characteristics used for 
cSS detection and the rating methods used for cSS classification. 
Quality and risk of bias assessment 
We assessed each study against a list of quality criteria we devised based on study size, cohort 
recruitment method (prospective vs. other), blinding of cSS ratings and APOE genotype data, 
quality of genotyping, blood-sensitive MRI sequence type used, criteria of cSS assessment and 
inter-rater agreement. These criteria were created using elements with reference to the 
STREGA (Strengthening the Reporting of Genetic Association Studies)16, MOOSE (Meta-
analysis of Observational Studies in Epidemiology)15 recommendations and consensus 
standards for cSS assessment and rating.1 
Statistical analysis and synthesis 
We performed meta-analyses using Stata 13.0 (StataCorp LP, Texas) and considered a p value 
of <0.05 to imply statistical significance. In our primary analyses, we calculated study-specific 
and random effects pooled, unadjusted ORs for cSS presence vs. absence among e4 allele 
carriers (e4+) versus the reference genotype e3e3 and among e2 carriers (e2+) versus the 
wild type e3e3. This comparison was selected, to avoid potential confounding by mixed effects 
of e2 and e4 in the comparison group. In secondary analyses, we compared cSS severity (focal 
vs. no cSS and disseminated vs. no cSS) in participants with an e2+ or e4+ genotype vs. the 
e3/e3 genotype. In analyses looking at cSS severity (i.e. focal or disseminated cSS) the 
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comparison groups included only patients without cSS. Meta-analyses were performed both 
separately by study setting/population, and overall. In all analyses we used a random effects 
model with DerSimonian-Laird weights,17 using odds ratios (OR) and their corresponding 95% 
CIs, with the inverse variance method for weighting. We assessed statistical heterogeneity 
using I-squared statistics and visually through inspection of the forest plot. Values of ≤25%, 
25% to 50%, and ≥50% were defined as low, moderate, and high degrees of heterogeneity, 
respectively. We explored publication bias with funnel plots. As a subanalysis, and to reveal 
potential dose-effect relationships, we have also explored the association between all different 
APOE genotypes (i.e. e2 e3, e3e4, e4e4, e2e2, e2e4 vs. e3e3) and cSS presence and severity 
in the whole population and across different clinical settings. To assess robustness of the 
methods, we repeated all the above analyses using the fixed effects method. 
Data availability statement 
All relevant data and methods are reported in the manuscript. No data available in public 
repositories. 
Results 
Characteristics and quality of included studies 
From 33 publications identified in our literature search, we identified 13 relevant studies 
fulfilling our inclusion criteria and pooled in meta-analyses (Figure 1). Study populations 
comprised seven memory clinic cohorts (n=2587), five symptomatic non-overlapping CAA 
cohorts (n=402) and one population based study including healthy people (n=1379) (Table 1). 
The memory clinic studies had different inclusion criteria and dementia prevalence (Table 1). 
The symptomatic CAA studies included two cohorts presenting with stroke syndromes other 
than ICH, one with pure CAA-ICH, and two with both CAA-ICH and CAA non-ICH 
presentations. Four out of these five CAA cohorts were derived from different studies 
completed at the same centre,4, 18-20 but included largely non-overlapping patient cohorts (i.e. 
different clinical settings/recruitment, clinical presentation, inclusion criteria, inception etc.). 
In detail (see footnote in Table 1), one of these four single centre cohorts,4 an advanced 
research MRI study of CAA-related ICH patients have included around 10% of overlapping 
patients with a separate consecutive clinical ICH cohort,19 from which CAA-related lobar ICH 
were included in our analysis, based on our best estimates. This latter clinical CAA cohort19 
might have slightly overlapped (~10%) with a pathology-based cohort of CAA patients.20 Mean 
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age was between 63-75 years and about half of all participants were male. Most studies were 
conducted in predominantly white populations in centres from Europe, USA or Australia, 
while two studies were conducted on Asia. The distribution of the ethnicity of participants in 
each study was not available. 
There was variation in overall study quality (Table 2), including sample size and 
retrospective vs. prospective designs. The genotyping quality was generally good when 
assessed against current reporting standards. Studies varied in the type of blood-sensitive 
sequences used for cSS detection (e.g. T2*-GRE vs. SWI), as well as MRI field strength, with 
all cohorts on symptomatic CAA patient populations using 1.5 T MRI, while memory clinic 
studies were performed at 3T MRI. The methods of cSS assessment were reliable and largely 
in line with current consensus recommendations in the field.1 For details on quality assessment 
and individual scores of included studies in the meta-analysis, see Table 2. 
Pooled prevalence and severity of cSS in included studies 
The pooled prevalence of cSS presence was 2% (95%CI: 2%-3%, I2: 59%, p=0.02) in memory 
clinic patients, 47% (95%CI: 38%-56%, I2: 66%, p=0.02) in symptomatic CAA patients and 1% 
(95%CI: 1%-2%) in the single population-based study included in our analysis. The overall 
pooled prevalence of focal cSS in memory clinic vs. symptomatic CAA patients was 1% (95%CI: 
1%-2%, I2: 48%, p=0.07) and 17% (95%CI: 13%-22%, I2: 24%, p=0.26) respectively. The overall 
pooled prevalence of disseminated cSS was 1% (95%CI: 0%-1%, I2: 9%, p=0.36) vs. 28% (95%CI: 
20%-36%, I2: 60%, p=0.04) in memory clinic vs. symptomatic CAA cohorts respectively. In all 
comparisons, the prevalence of cSS (presence and severity) was higher in symptomatic CAA 
vs. memory clinic patients (p<0.0001). Among patients with any cSS, the prevalence of focal 
cSS was 67% (95%CI: 55%-79%, I2: 17%, p=0.30) in memory clinic patients and 37% (95%CI: 
26%-49%, I2: 60%, p=0.04) in symptomatic CAA cases (p<0.001 between the two groups). 
Meta-analyses: APOE e4 and e2 and cSS presence and severity 
The results of the main analyses of the association between APOE e4 and e2 with cSS 
presence are summarised in Figure 2. Compared to participants with an APOE e3/e3 
genotype, pooled overall results showed no increased odds of cSS presence in participants 
with APOE e4+ genotype (Figure 2A). When stratified by clinical subgroups, APOE e4+ 
genotype was associated with cSS presence in memory clinic patients, but not symptomatic 
CAA patients (Figure 2A). The pooled OR showed increased odds of having cSS for APOE 
e2+ genotypes (OR 2.67, 95%CI: 2.31-3.08) with no statistical heterogeneity between study 
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results (Figure 2B). This association was strong in both memory clinic and symptomatic CAA 
cohorts (Figure 2B). 
All clinical studies provided relevant data for meta-analyses of APOE genotypes and cSS 
severity (focal or disseminated). These data were not available to pool in the single population-
based study which reported on APOE and cSS. Overall, pooled results showed that, compared 
to patients with an e3/e3 genotype, those with an e4 + genotype did not have increased odds 
of having either focal or disseminated cSS (Figure 3A). Memory clinic patients showed only a 
non-significant trend for an association with APOE e4 + genotype and cSS burden (Figure 3A). 
Overall, patients with APOE e2+ genotype had increased odds for an association with 
disseminated, but not focal, cSS (Figure 3B). When stratified by clinical setting, focal cSS was 
associated with APOE e2+ genotype in memory clinic patients, and showed a strong trend 
with disseminated cSS in this population (Figure 3B). In symptomatic CAA cohorts, only 
disseminated cSS was associated with APOE e2+ genotype. There was no evidence of 
publication bias and statistical heterogeneity was low to moderate across analyses (data 
provided in each forest plot) 
Subgroup meta-analyses: different APOE genotypes and cSS presence and 
severity 
The detailed results of subanalyses exploring the association between all different APOE 
genotypes (vs. e3/e3) and cSS presence and burden are summarised in Table 3. In the overall 
analysis of all the cohorts together, the most consistent associations with higher effect sizes 
were seen with APOE e2/e2 and APOE e2/e4 genotypes (Table 3). The associations were 
different when stratified by the clinical setting. In memory clinic cohorts, cSS presence and 
severity was also associated with APOE e4/e4, while the stronger link was with the APOE 
e2/e4 genotype (Table 3). Among symptomatic CAA cohorts, only APOE e2/e3 and APOE 
e2/e4 were associated with disseminated cSS (Table 3). Of note, the APOE e4/e4 genotype 
was associated with marginally lower odds of having disseminated cSS in symptomatic CAA 
patients (OR: 0.24; 95%CI: 0.06-0.92, p=0.038, see Table 3). The statistical heterogeneity for 
these subanalyses ranged from low, to moderate and high (Table 3). 
Discussion 
The current meta-analysis provides a comprehensive assessment on cSS,1 CAA,21 and their 
association with APOE genotype. Drawing data from >4000 participants of relevant studies 
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and different clinical setting, our main results indicated that cSS, especially disseminated cSS, 
is most strongly associated with APOE e2+ genotype. This overall association was consistent 
and did not vary significantly according to clinical setting. We found that APOE e4+ genotype 
was overall not associated with cSS presence or burden. However, APOE e4+ genotype 
results varied depending on the clinical setting, with memory clinic patients (but not 
symptomatic ICH patients) showing an association with cSS, albeit weaker compared to APOE 
e2+ genotype based on the unadjusted pooled ORs (2.10 versus 3.28 respectively). In the 
detailed subanalyses looking at individual APOE genotypes and cSS burden, the most 
consistent associations with higher effect sizes were seen with the e2/e2 and e2/e4 genotypes. 
Although it can be challenging to infer specific pathophysiological mechanisms from 
genetic associations, the most straightforward and parsimonious explanation for our results 
is that cSS is indeed a strong and specific MRI biomarker for more advanced or active CAA. 
These results confirm our prespecified hypothesis, are consistent with prior observations in 
the field, with what is presumed to be the effect of APOE e2 vs. e4 on underlying CAA-
related vasculopathic changes, and with the emerging clinical relevance of cSS as an 
independent risk factor for future symptomatic ICH. APOE genotype is the single most 
important genetic determinant in CAA pathophysiology.10, 11 APOE e4 appears to enhance 
vascular amyloid-β deposition in a dose-dependent fashion,12 while APOE e2 promotes 
vasculopathic changes (vessel cracking, vessel-within-vessel appearance and fibrinoid necrosis) 
which can lead to vessel rupture.13 A previous meta-analysis investigating APOE associations 
with cerebral microbleeds found that strictly lobar microbleeds (a putative marker of CAA 
presence) was related to APOE e4 + allele (OR: 1.35, 95%CI: 1.10–1.66, p=0.005), but not 
APOE e2.22 This result was consistent for any cerebral microbleeds presence in a more recent 
comprehensive meta-analysis.23 The dissociation of the relationship between APOE genotype 
and cerebral microbleeds vs. cSS has implications for discerning potential mechanisms. APOE 
e4 might predispose to the particular kind of CAA-related vessel thickening postulated to 
lead to microscopic intraparenchymal hemorrhage (e.g. strictly lobar cerebral microbleeds).24 
In contrast, APOE e2 might promote the most severe stages or aggressive phenotype of CAA 
pathology that precede rupture, especially in leptomeningeal vessels, hence contributing to 
MRI-visible superficial CAA-related bleeds (aka cSS) in multiple spatially separated foci.4, 20 A 
recent neuropathological study used a detailed grading system for assessing CAA in 
parenchymal and leptomeningeal vessels separately.25 In a sample of Alzheimer’s disease and 
non-demented elderly control brains, APOE e2 was a much stronger risk factor for CAA 
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development, especially in leptomeningeal vessels, compared to APOE e4 (OR: 10.93; 95%CI: 
4.33-27.57 vs. 1.69; 0.92-3.10, respectively).25 Fittingly, an inverse relationship has been 
observed between greater lobar cerebral microbleed counts and cSS in advanced CAA, 
suggesting the possibility of differing CAA phenotypes that are driven in part by APOE 
genotype, and marked by the predominance of either cSS or CMBs MRI patterns.4,22 
These inferences would also be in line with several clinical observations in the field. 
APOE e2 is already known to be associated with CAA-related ICH, perhaps causally,26 also 
predisposing to larger volumes of CAA-related bleeding.27 cSS is independently associated 
with future ICH risk in CAA, both recurrent6, 28 and first lobar ICH.5 In fact, clinical cohorts 
which incorporated and investigated both cSS and strictly lobar microbleeds in relation to 
future ICH, demonstrated that cSS, but not microbleeds, is the strongest independent risk 
factor for CAA-ICH.5, 6, 28 Also, there is preliminary evidence that APOE e4 may be associated 
with CAA type 1 (where CAA is found in cortical capillaries) and APOE e2 with CAA type 2 
(where cerebrovascular amyloid is primarily deposited in leptomeningeal and cortical vessels 
sparing cortical capillaries).29 A recent neuropathological study which validated a detailed CAA 
grading system showed that all individuals with the APOE e2/e2 genotype had CAA-type 2, 
while the APOE e4/e4 genotype was associated with CAA type 1 (OR 8.0; 95% CI 2.8-23.3).25 
Finally, though the exact pathophysiological mechanisms underlying cSS remain debatable,1 
MRI-detected cSS seems to reflect repeated episodes of superficial bleeding from CAA-laden 
bleeding-prone leptomeningeal vessels.1 Thus cSS may be a strong marker of not only more 
severe CAA, but CAA with more fragile, rupture-prone vessels, thereby, heralding a risk of 
subsequent ICH.6, 30 APOE e2 driven vascular injury in CAA, in combination with other risk 
factors, could influence pathways providing initiation sites for cSS and hence future lobar ICH 
risk. 
Our study benefited from thorough ascertainment of the totality of evidence to date on 
the topic, within the two clinical settings in which CAA is most commonly considered. The 
first setting consists of patients diagnosed in stroke clinics with relatively advanced 
symptomatic CAA, while memory clinic patients and healthy elderly are heterogeneous 
participants who mostly do not have advanced CAA (instead, mild to moderate CAA 
commonly accompanies Alzheimer’s neurodegenerative pathology in memory clinic patients). 
This fact explains the much higher proportion of cSS in the symptomatic CAA group and 
might partly account for the different relationship with APOE e4. We note the higher 
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frequency of APOE e4 in patients from memory clinics, at least in part, due to the relationship 
between this genotype and its well-known predisposition to Alzheimer’s disease (instead, 
APOE e2 variant confers reduced risk for Alzheimer’s disease and thus has lower frequency 
in memory clinics).31 Similar to Alzheimer’s disease, as noted above, histopathological studies 
in CAA indicate that APOE e4 has an equivalent role in CAA by promoting vascular amyloid-
β deposition; APOE e2 however, has a different effect - it increases vessel wall damage caused 
by cerebrovascular amyloid deposition. In other words, the hypothesis is that APOE e4 
increases the likelihood of having CAA among memory clinic patients (identified clinically by 
the presence of cSS). Among symptomatic CAA patients with already advanced (or enriched 
in) underlying cerebrovascular amyloid deposition, it doesn’t increase the likelihood of cSS – 
in this group, APOE e2 comes into play (especially in a dose-depended and synergistic fashion 
with APOE e4 gene). 
Our findings in the subanalyses of detailed APOE genotypes and associations with cSS 
presence and burden, probably account for the prevalence and differential effects of e4 and 
e2 in Alzheimer’s disease and CAA. However, these subanalyses need to be interpreted with 
caution, under the prism of the following additional considerations. The relatively small sample 
size contributing to each subanalysis (e.g. according to clinical setting, focal or disseminated 
cSS etc.) and rarity of certain alleles and genotypes, resulted in wide 95% confidence intervals. 
Due to the increased number of subanalyses, we run the risk of multiple comparisons. Hence, 
they should be considered hypothesis-generating, highlighting possible trends, effect sizes and 
potential mechanistic pathways to be explored in further studies on cSS. It is important to 
again point out that the associations between cSS presence/burden and specific APOE 
genotypes, require, to some extent, different interpretation in memory clinic vs. symptomatic 
CAA cohorts. In memory clinic patients, APOE genotype-cSS associations are driven by the 
presence of substantial underlying CAA pathology that is denoted by cSS. In other words, cSS 
in memory clinic cohorts, identifies patients with advanced CAA (i.e. beyond the mild CAA, 
often a common “innocent bystander” in this setting) - the known risk factor of originally 
developing cerebrovascular amyloid-β accumulation is APOE e4 and e2. Symptomatic CAA 
cohorts, are by definition enriched with cerebrovascular amyloid-β pathology and hence 
APOE-cSS associations are driven/indicating more specific (or predominant) 
pathophysiological mechanisms at play, especially within the most severe cases of cSS (i.e. 
disseminated cSS). It is possible that the APOE e2/e4 genotype may represent double hit for 
the superficial vessels, promoting not only amyloid deposition but also vessel wall cracking in 
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the most vulnerable arterioles in CAA. In the setting of advanced cerebrovascular amyloid-β 
pathology, it is not surprising that only this ‘double hit’ genotype of APOEe2/APOEe4 shows 
a strong link with disseminated cSS. These hypotheses require external validation and direct 
support from experimental studies. Future studies should also investigate the effect of APOE 
genotypes on cSS progression and interactions with future CAA-related ICH risk. 
Some limitations of our study need to be acknowledged. The design of included studies, 
case selection, and MRI parameters for cSS detection were variable. Patients from 
symptomatic CAA cohorts underwent brain MRI at I.5T, while other cohorts at 3T. While 
the consisted MRI field strength within clinical setting sub-groups is reassuring, in the overall 
analyses, the difference could influence the sensitivity for cSS detection and rating. In the same 
vein, blood-sensitive sequences used for cSS detection were also variable across studies, 
including both T2*-GRE and SWI. Though the variable MRI parameters is a potentially 
important limitation for this sort of meta-analysis, no data exist on how sensitivity for cSS 
classification is affected by different MRI sequences. Considering that cSS represents a much 
higher volume of blood-breakdown products (i.e. hemosiderin) compared for example to 
cerebral microbleeds, the differences in MRI sensitivity might not be very pronounced. None 
of the included studies fulfilled all our methodologic quality indicators. There is likely a number 
of studies that could not be included in the current meta-analysis simply because they did not 
report on either APOE or cSS, reflecting the fact that cSS is a relatively new addition in the 
spectrum of CAA MRI markers. This raises the issue of potential confounding and selection 
bias, which is hard to address. It should be emphasised that, despite including all available data 
from relevant publications, the overall sample size for certain subgroup meta-analyses was 
relatively small. This limits the precision of the pooled results, especially in combination with 
the low prevalence of cSS in the memory clinic studies. In a memory clinic setting, one should 
recognise the known relative rarity of APOE e2 genotypes and the confounding effect of the 
presence of dementia and Alzheimer’s type pathology. While CAA and Alzheimer’s disease 
are linked in the context of cognitive impairment populations, their precise relationship 
remains poorly understood.32 This and other considerations could partly explain the weak 
association observed between cSS presence and APOE e4 in the memory clinic cohorts. For 
example, both CAA and neurodegenerative pathology contribute to cognitive impairment in 
the elderly33 and APOE e4 is a well-known risk factor for both cerebrovascular and 
parenchymal amyloid accumulation. Nevertheless, quite reassuringly, the association with 
APOE e2 and cSS was consistently detected in memory clinic patients and with stronger effect 
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size than the APOE e4 association. Lastly, our meta-analysis was performed at a group level, 
which means that generated pooled estimates are not adjusted for any confounders that might 
influence the association between APOE status and cSS, including age, sex and other MRI 
markers of small vessel disease. It is thus possible that reported associations are overstated. 
It could be argued that our unadjusted group-level meta-analysis is exploratory, providing a 
rough indication of likely effect sizes across populations for the APOE-cSS link, setting the 
scene for a more detailed individual-patient level meta-analysis. We are hoping to pursue this 
in the future in a large collaborative study. 
Most of the symptomatic CAA cohorts suitable for meta-analysis came from a single 
centre. We acknowledge the potential for some overlap among these cohorts – while we do 
not have all the detailed data on overlapping patients, based on the different clinical 
setting/recruitment, clinical presentation, inclusion criteria, inception points etc., this overlap 
is minimal and ranges between 5-10%, as summarised in Table 1 footnote. Any potential 
overlap between these cohorts is random and unlikely to have affected our main results. 
However, due to this limitation, our findings will benefit from further validation and updated 
meta-analyses. The plausible suggestion of different APOE influences on the severity and type 
of amyloid deposition in the vessel wall and advanced vasculopathic changes suggested in the 
interpretation of our current findings, are based on limited data.34 In particular, further studies 
on the proposed differential effects of e4 and e2 alleles will be valuable. However, it is 
reasonable to provide an informed discussion based on these biological hypotheses and 
assumptions, in an effort to start building a pathophysiology model of cSS that could explain 
both clinical and research findings and help develop hypothesis-driven studies in the field. 
Finally, the vascular damage pathways leading to cSS must be only partly influenced by APOE 
e2 as evidenced by the fact that a number of cSS cases are also found within the APOE e3/e3 
genotype. 
Notwithstanding these caveats, our results provide useful data to partly settle the 
question in favor of a link between APOE e2+ genotype and cSS in CAA. The pathophysiologic 
implication is that APOE e2 influences the risk of cSS through promoting the most severe 
stages of CAA pathology that are associated with rupture. These results are also in line with 
cSS being a strong hemorrhagic MRI signature in CAA and the likely “smoking gun” of bleeding 
risk. Future research efforts on the topic require methodologically robust, large studies 
adhering to current reporting standards,1, 35 and collaborative data pooling efforts. Based on 
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the totality of current evidence, our study suggests a biologically meaningful association 
between the APOE e2 + genotype and severe cSS in patients with CAA, probably as a result 
of the role of e2 in the severity of vasculopathy in CAA-affected leptomeningeal and very 
superficial cortical vessels. The exact pathophysiological mechanisms that underlie these 
associations should be investigated, as they might define targets for therapeutic interventions 
in CAA. 
  
 16 
Authors and their individual contributions to the manuscript 
Name Location Role Contribution 
Andreas 
Charidimou 
MGH, Boston, MA, USA Author 
Study concept and design, data collection, 
statistical analysis, write up, revisions, study 
supervision 
Hazel I. 
Zonneveld 
VU University Medical 
Center, Amsterdam, 
the Netherlands 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Sara Shams 
Karolinska University 
Hospital, Stockholm, 
Sweden 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Kejal 
Kantarci 
Mayo Clinic, Rochester, 
MN, USA Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Ashkan 
Shoamanesh 
McMaster University, 
Hamilton, Ontario,, 
CAN 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Saima Hilal 
National University of 
Singapore, Singapore Author Major role in the acquisition of data 
Paul A. Yates 
The University of 
Melbourne, Parkville, 
Australia 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Gregoire 
Boulouis 
MGH, Boston, MA, USA Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Han Kyu Na 
Samsung Medical 
Center, Seoul, Republic 
of Korea 
Author Revised the manuscript for intellectual content 
Marco Pasi MGH, Boston, MA, USA Author Revised the manuscript for intellectual content 
Allesandro 
Biffi 
MGH, Boston, MA, USA Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Yuek Ling 
Chai 
National University of 
Singapore, Singapore Author Revised the manuscript for intellectual content 
Joyce Ruifen 
Chong 
National University of 
Singapore, Singapore 
Author Revised the manuscript for intellectual content 
Lars-Olof 
Wahlund 
Karolinska University 
Hospital, Stockholm, 
Sweden 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
 17 
Jack R. 
Clifford 
Mayo Clinic, Rochester, 
MN, USA Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Christopher 
Chen 
National University of 
Singapore, Singapore 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
M. Edip 
Gurol 
MGH, Boston, MA, USA Author Revised the manuscript for intellectual content 
Joshua N. 
Goldstein 
MGH, Boston, MA, USA Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Duk L. Na 
Samsung Medical 
Center, Seoul, Republic 
of Korea 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Frederik 
Barkhof 
VU University Medical 
Center, Amsterdam, 
the Netherlands 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Sang Won 
Seo 
Samsung Medical 
Center, Seoul, Republic 
of Korea 
Author 
Major role in the acquisition of data, revised the 
manuscript for intellectual content 
Jonathan 
Rosand 
MGH, Boston, MA, USA 
Author 
Major role in the acquisition of data, obtaining 
funding, revised the manuscript for intellectual 
content 
S. M. 
Greenberg 
MGH, Boston, MA, USA 
Author 
Major role in the acquisition of data, obtaining 
funding, revised the manuscript for intellectual 
content 
A. 
Viswanathan 
MGH, Boston, MA, USA 
Author 
Design and conceptualized study, interpreted the 
data, revised the manuscript for intellectual 
content, study supervision 
  
 18 
Funding and disclosures 
A. Charidimou: study concept and design, data collection, statistical analysis, write up 
Hazel I. Zonneveld: data collection, critical revisions 
Sara Shams: reports no disclosures. 
Kejal Kantarci: reports no disclosures. 
Ashkan Shoamanesh: reports no disclosures. 
Saima Hilal: reports no disclosures. 
Paul A. Yates: reports no disclosures. 
Gregoire Boulouis: reports no disclosures. 
Han Kyu Na: reports no disclosures. 
Marco Pasi: reports no disclosures. 
Allesandro Biffi: reports no disclosures. 
Yuek Ling Chai: reports no disclosures. 
Joyce Ruifen Chong: reports no disclosures. 
Lars-Olof Wahlund: reports no disclosures. 
Jack R. Clifford: reports no disclosures. 
Christopher Chen: reports no disclosures. 
M. Edip Gurol: reports no disclosures. 
Joshua N. Goldstein: reports no disclosures. 
Duk L. Na: reports no disclosures. 
Frederik Barkhof: reports no disclosures. 
Sang Won Seo: reports no disclosures. 
Jonathan Rosand: reports no disclosures. 
S. M. Greenberg: reports no disclosures. 
A. Viswanathan: reports no disclosures. 
 
Study Funding: This work was supported by The Genetics of Cerebral Hemorrhage with 
Anticoagulation study, funded by National Institutes of Health (NIH)/NINDS grant R01NS059727. This 
study is not industry sponsored. Andreas Charidimou is supported by a Bodossaki Foundation post-
doctoral scholarship. 
 19 
Tables 
Table 1. Basic characteristics and methodological aspects of included studies. 
Study 
Country 
(period) 
Setting-Participants 
source 
Study 
size* 
Mean 
age 
Male 
(%) 
Dementia 
(%) 
MRI 
sequence 
Field 
strength 
ET 
(ms) 
ST 
(mm) 
cSS rating 
CAA cohorts 
†Charidimou et al. 
201718 
USA 
Probable CAA without ICH – 
stroke clinic 
62 75 57% 10% T2*-GRE 1.5T 50 5 
2 trained raters 
by consensus 
†Charidimou 201619 USA Clinical CAA-ICH 197 74 49% ? T2*-GRE 1.5T 50 5 
1 trained rater 
(k=) 
†Charidimou 201520 USA Pathologically-proven CAA 53 73 45% ? T2*-GRE/SWI 1.5T - - 1 trained rater 
†Shomanesh 20144 USA CAA research cohort 79 71 70% 10% T2*-GRE/SWI 1.5T 25 5 
1 trained rater 
(k=0.79) 
Martínez-Lizana et 
al. 201536 
Spain 
Convenience biomarkers 
cohort of CAA patients with 
and without cSAH 
25 79 52% 28% T2*-GRE 1.5T - - Not reported 
Memory clinic/non-symptomatic CAA cohorts 
Shams 201637 Sweden 
Consecutive memory clinic 
series 
520 63 47% 35% T2*-GRE/SWI 3T - - 
2 trained raters 
by consensus 
†Charidimou 201638 USA 
Consecutive memory clinic 
series 
68 73 44% 43% T2*-GRE 3T 
20-
25.7 
5 1 trained rater 
Na 201539 Korea 
Memory clinic patients with 
PET/MRI/CSF analysis 
232 72 42% ? T2*-GRE 3T   
2 trained raters 
(k=0.92) 
Zonneveld 201440 
Netherlands 
(2010-2012) 
Memory clinic–based 
Amsterdam Dementia Cohort 
610 66 56% 41% SWI 3T - - 
1-2 trained 
raters (k=0.81) 
Yates 201441 Australia 
Melbourne Neuroimaging 
Cohort of the Australian 
Imaging, Biomarkers and 
Lifestyle Study of Ageing 
174 74 40% 23% SWI 3T - - 
2 trained raters 
(k~0.8) 
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Kantarci 201342 
ADNI 
(2010-2012) 
Alzheimer’s Disease 
Neuroimaging Initiative 
(ADNI) 
451 73 55% 8% T2*-GRE 3T - - Trained raters 
Singapore cohort Singapore Memory clinics in two centres 458 ~70 51% 34% SWI 3T 20 1 Trained raters 
Population-based cohorts 
Pichler at al. 201743 
USA (2011-
2016) 
Mayo Clinic Study of Aging 1412 62-78 53% <9% T2*-GRE 3T 20 3.3 Trained raters 
* number of eligible participants genotyped and assessed for cSS; R: retrospective study; P: prospective study; ?:unknown 
† Cohorts originating from a single centre (Massachusetts General Hospital-MGH). We note minimal sample overlap among these included studies and cohorts 
originating from MGH. Most of these different cohort are completely independent (i.e. different clinical setting/recruitment, clinical presentation, inclusion criteria, 
inception etc.). However, there is a possibility of ~5-10% (or lower) overlap between 3 of the MGH cohorts (Ref. 4, 19 and 20). Please note that it is not possible to 
definitely identify potentially overlapping patients among the two cohorts and exclude them, due to different coding and anonymization of the patient data and 
samples.  
In detail:  
-Ref. 4: MGH ICH/CAA cohort since 1995 – this is a research, advanced MR imaging CAA-ICH cohort. None of the patients are included in cohorts corresponding 
to Ref. 20, 18 or 35. Around 10% of the patients might be overlapping with Ref. 18. 
-Ref. 20: MGH 1997-2012 – this is a neuropathology-based cohort of CAA patients, irrespective of clinical presentation, with available tissue. Around 5% or less of 
the patients might be overlapping with Ref. 19. 
-Ref. 18: MGH stroke and memory 1994-2015 – this is a “probable CAA” cohort according to the modified Boston criteria of patients presenting without ICH, in 
stroke clinics or specialty CAA clinics at our group. There is no overlap with Ref. 4, 19, or 20. 
-Ref. 19: MGH ICH cases – this is an consecutive clinical ICH cohort, from which CAA-related lobar ICH were included in our analysis. The cohort might be 
overlapping by 10% with Ref. 4 and Ref. 20 cohorts.  
-Ref. 35: MGH memory clinic 2007-2010 – a generic, unselected memory clinic patient cohort (without ICH or stroke-like syndromes), not overlapping with any of 
the other MGH cohorts cited in our paper. 
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Table 2. Summary of key quality indicators of pooled studies. 
Study Reference 
Study size 
Design  
(R-0, P-1) 
Blinding 
(MRI to 
genotype) 
cSS 
criteria 
clearly 
defined 
cSS inter-
observer 
agreement 
T2*-GRE (0) vs. 
SWI (1) 
Genotyping 
reporting 
Total score 
(0-8) 
≤100 
101-
200 
>200 
Charidimou et al. 
201718 
✓    0 ✓  ✓  ✓  0 1 4 
Charidimou 201619  ✓   0 ✓  ✓  X 0 1 4 
Charidimou 201520 ✓    0 ✓  ✓  X 0 1 3 
Shomanesh 20144 ✓    1 ✓  ✓  X 0 1 4 
Martínez-Lizana et 
al. 201536 
✓    0 ✓  ✓  X 0 1 3 
Shams 201637   ✓  0 ✓  ✓  ✓  0 1 6 
Charidimou 201638 ✓    0 ✓  ✓  X 0 1 3 
Na 201539   ✓  1 ✓  ✓  ✓  0 1 7 
Zonneveld 201440   ✓  1 ✓  ✓  ✓  1 1 8 
Yates 201441  ✓   1 ✓  ✓  ✓  1 1 7 
Kantarci 201342   ✓  0 ✓  ✓  X 0 0 4 
Singapore cohort   ✓  1 ✓  ✓  X 1 1 7 
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Pichler at al. 201743   ✓  1 ✓  ✓  x 0 1 6 
 
Scoring system: For each key quality indicator listed, each study got 1 point if fulfilled. For the design “Design” criterion, studies got 1 point if 
they were prospective (P-1) and 0 points if retrospective (R-0). For blood-sensitive MRI sequences, accounting for the different sensitivities in 
detecting and assessing cSS, studies got 1 point if they used susceptibility-weighted imaging (SWI-1) and 0 points if they used T2*-weighted 
gradient-recalled echo (T2*-GRE-0). For study sizes, studies got 0-2 points depending on the number of included patients, i.e. ≤100, 101-200 
or >200 patients, respectively. The total score was calculated by adding all the points for each individual key quality indicator, thus ranging 
from 0 (lowest quality) to 8 (highest quality). 
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Table 3. Detailed meta-analyses results for the association between different APOE 
genotypes (vs. e3/e3) and cSS presence and burden. For the analyses including focal cSS and 
disseminated cSS, the comparison groups included only patients without cSS. 
 APOE 
genotype 
e4/e3 e4/e4 e2/e3 e2/e2 e2/e4 
O
V
E
R
A
L
L
 
cSS presence      
OR (95%CI) 
0.87 (0.41-1.83) 
p=0.712 
1.27 (0.49-3.28) 
p=0.617 
2 (1.20-3.32) 
p=0.008 
3.41 (1.13-10.3) 
p=0.029 
3.96 (1.85-8.51) 
p<0.0001 
Heterogeneity 52.5%, p=0.017 63.2%, p=0.002 0%, p=0.804 0%, p=0.530 8.5%; p=0.362 
Focal cSS      
OR (95%CI) 
0.85 (0.40-1.82) 
p=0.683 
1.53 (0.67-3.50) 
p=0.312 
1.56 (0.78-3.12) 
p=0.213 
6.01 (1.53-23.59) 
p=0.010 
3.85 (1.52-9.78) 
p=0.005 
Heterogeneity 31.4%; p=0.140 36%; p=0.102 0%; p=0.563 4.4%; p=0.388 9.7%; p=0.351 
Disseminated cSS 11 10 9 7 9 
OR (95%CI) 
0.93 (0.46-1.87) 
p=0.839 
0.96 (0.28-3.28) 
p=0.951 
2.64 (1.38-5.06) 
p=0.003 
5.29 (1.60-17.55) 
p=0.006 
5.61 (2.45-12.84) 
p<0.0001 
Heterogeneity 13.4%; p=0.316 53.5%; p=0.022 0%; p=0.696 0%; p=0.639 0.8%; p=0.427 
M
E
M
O
R
Y
 C
L
IN
IC
 C
O
H
O
R
T
S
 
cSS presence      
OR (95%CI) 
1.60 (0.60-4.23) 
p=0.347 
4.63 (2.14-10.02) 
p<0.0001 
3.41 (1.45-8.01) 
P=0.005 
11.72 (2.33-58.8) 
P=0.003 
7.12 (2.25-22.56) 
P=0.001 
Heterogeneity 35.1%; p=0.161 0%; p=0.848 0%; p=0.906 0%; p=0.834 0%; p=0.617 
Focal cSS      
OR (95%CI) 
1.49 (0.61-3.66) 
p=0.383 
4.79 (1.99-11.52) 
P<0.0001 
2.92 (1.05-8.12) 
P=0.40 
17.37 (3.34-172.1) 
P=0.001 
7.35 (2.25-24.0) 
P=0.001 
Heterogeneity 0%; p=0.466 0%; p=0.981 0%; p=0.986 0%; p=0.934 0%; p=0.939 
Disseminated cSS      
OR (95%CI) 
2.17 (0.70-6.74) 
p=0.179 
5.32 (1.53-18.53) 
P=0.009 
5.04 (1.24-20.42) 
P=0.023 
18.09 (2.67-122.5) 
P=0.003 
10.21 (1.65-63.26) 
P=0.013 
Heterogeneity 0%; p=0.679 05; p=0.716 0%; (p=0.570) 0%; p=0.706 21.1%; p=0.283 
S
Y
M
P
T
O
M
A
T
IC
 C
A
A
 C
O
H
O
R
T
S
 cSS presence      
OR (95%CI) 
0.47 (0.17-1.32) 
p=0.151 
0.32 (0.13-0.77) 
P=0.11 
1.49 (0.79-2.81) 
P=0.213 
1.15 (0.25-5.23) 
P=0.857 
2.94 (0.93-9.34) 
P=0.067 
Heterogeneity 56.5%; p=0.056 20.5%; p=0.284 0%; p=0.646 0%; p=0.802 26.1%; p=0.247 
Focal cSS      
OR (95%CI) 
0.51 (0.15-1.68) 
p=0.268 
0.41 (0.16-1.04) 
P=0.060 
0.83 (0.24-2.87) 
P=0.767 
0.77 (0.08-7.60) 
P=0.825 
2.13 (0.30-15.24) 
P=0.451 
Heterogeneity 46.5%; p=0.113 0%; p=0.759 32.6%; p=0.204 0%; p=0.738 52.6%; p=0.096 
Disseminated cSS      
OR (95%CI) 
0.57 (0.23-1.42) 
p=0.224 
0.24 (0.06-0.92) 
P=0.038 
2.22 (1.38-5.06) 
P=0.033 
2.39 (0.51-11.12) 
P=0.268 
4.56 (1.76-11.84) 
P=0.002 
Heterogeneity 24.1%; p=0.261 33.4%; p=0.199 0%; p=0.643 0%; p=0.639 0%; p=0.460 
Heterogeneity (I2, p-value)  
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Figures 
 
 
Figure 1. Flow chart of study identification and selection. 
  
33 unique 
recordsS
e
ar
ch
PubMed
n=19
S
cr
e
e
n
in
g
16 records screened
-Excluded on title/abstract
(not relevant: reviews, editorial, 
cases, non-human studies) 
n=17
16 full-text assessed 
E
lig
ib
ili
ty
Excluded (n=3)
-no appropriate control (n=1)
-overlapping cohorts (n=1)
-no cSS assessment (n=1)
13 studies analysedA
n
al
ys
is
Web of Science
n=25
 25 
 
Figure 2. Forest plots of the association between cSS presence and (A) APOE e4+ vs APOE 
e3/e3 genotype, and (B) APOE e2+ vs APOE e3/e3 genotype. Meta-analyses were performed 
Overall:	p=0.512		(I2=53.1%,	p=0.012)
Charidimou	et	al.	2017
Shomanesh	et	al.	2014
Zonneveld	2014
Charidimou	et	al.	2015
Symptomatic	CAA
Study
Singapure	memory	cohort
Charidimou	et	al.	2017
Kantarci	2013
Pichler	et	al.	2017
Yates	et	al.	2014
Na	et	al.	2015
Shams	et	al.	2016
Subtotal:	0.159	(I2=49.5%,	p=0.095)
Subtotal:	0.023		(I2=0%,	p=0.445)
Charidimou	et	al.	2016
Martínez-Lizana et	al.	2014
Population-based
Memory	clinic
1.23	(0.66,	2.30)
0.69	(0.36,	1.32)
0.58	(0.17,	2.05)
1.09	(0.29,	4.10)
0.35	(0.08,	1.57)
0.62	(0.07,	5.58)
1.60	(0.51,	5.00)
7.20	(0.83,	62.18)
17.87	(0.96,	332.81)
6.60	(0.78,	56.19)
4.94	(1.00,	24.40)
1.58	(0.46,	5.47)
0.57	(0.27,	1.24)
2.10	(1.11,	3.99)
1.75	(0.17,	17.92)
0.04	(0.00,	0.49)
OR	(95%	CI)
100
13.99
9.87
9.45
8.48
5.39
10.64
5.54
3.56
5.59
7.91
9.97
47.60
48.84
5.00
4.63
Weight	(%)
10.1 10
Presence	of cSS	increased	with	ε4+	allelePresence	of cSS	decreased	with	ε4+	allele
A.	Forest	plot	of	the	association	between	ε4+	vs.	ε3/ε3	genotypes	and	cSS	presence
Overall:	p<0.0005		(I2=7.6%,	p=0.370)
Charidimou	et	al.	2017
Charidimou	et	al.	2015
Martínez-Lizana	et	al.	2014
Singapure	memory	cohort
Population-based
Charidimou	et	al.	2017
Charidimou	et	al.	2016
Pichler	et	al.	2017
Subtotal:	p=0.005		(I2=0%,	p=0.606)
Zonneveld	2014
Na	et	al.	2015
Shomanesh	et	al.	2014
Memory	clinic
Yates	et	al.	2014
Kantarci	2013
Shams	et	al.	2016
Symptomatic	CAA
Subtotal:	p=0.047		(I2=0%,	p=0.734)
2.42	(1.48,	3.95)
3.60	(0.91,	14.23)
1.00	(0.20,	5.08)
2.29	(0.08,	66.02)
1.34	(0.15,	12.22)
1.42	(0.67,	3.03)
6.00	(0.47,	76.71)
56.19	(3.20,	987.82)
3.28	(1.44,	7.44)
0.99	(0.11,	8.99)
11.00	(1.89,	64.13)
2.33	(0.62,	8.82)
7.33	(0.63,	84.85)
1.88	(0.08,	46.88)
2.20	(0.39,	12.32)
1.75	(1.01,	3.03)
100
11.31
8.36
2.09
4.70
29.55
3.58
2.85
33.84
4.71
7.20
11.99
3.87
2.28
7.50
63.31
10.1 10
Study OR	(95%	CI) Weight	(%)
Presence	of cSS	increased	with	ε2+	allelePresence	of cSS	decreased	with	ε2+	allele
B.	Forest	plot	of	the	association	between	ε2+	vs.	ε3/ε3	genotypes	and	cSS	presence
 26 
using a random effects model. Studies are displayed in order of publication date. The squares 
represent study-specific odds ratios (ORs), with their size proportional to their statistical 
weight. Diamonds represent pooled ORs, and their 95% CI, stratified by clinical setting and 
overall. 
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Figure 3. (A) Subanalyses summary results of the effect of APOE e4+ vs APOE e3/e3 
genotype on the presence of focal and disseminated cSS, according to clinical setting and 
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overall. (B) Subanalyses summary results of the effect of APOE e2+ vs APOE e3/e3 genotype 
on the presence of focal and disseminated cSS, according to clinical setting and overall. The 
comparison groups included only patients without cSS. The columns on the right of the forest 
plots denote the number of participants included in each analysis. Diamonds represent the 
overall pooled ORs, and their 95% CI for each comparison. Study-specific OR are not shown. 
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